RAF1 and hematologic disorder: SHP2 is a well-established major regulator of RAS-to-RAF-to-MAPK signal pathway and somatic gain-of-function SHP2 mutations or overexpression have also been identified in several hematologic malignancies as well as solid tumors such as gastric, breast, lung and pancreatic cancers and RASopathies1,2,6,23–25.